Director/PDMR Shareholding

RNS Number : 6177G
EKF Diagnostics Holdings PLC
08 May 2014
 



 

 

EKF Diagnostics Holdings plc

("EKF", the "Company")

 

Director / PDMR Shareholding

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, announces that Directors of the Company have today made the following share purchases:

 

Director

No. of ordinary shares purchased

Purchase price

Total shareholding before purchase

Total shareholding following purchase

Percentage of issued share capital

Julian Baines, Chief Executive Officer

100,000

25.07p

1,621,955

1,721,955

0.41%

David Evans, Executive Chairman

100,000

25.07p

1,605,753

1,705,753

0.40%

Paul Foulger, Chief Financial Officer

50,000

25.07p

3,438,589

3,488,589

0.83%

Richard Evans, Chief Operating Officer

25,000

25.07p

153,842

178,842

0.04%

Adam Reynolds, Non-Executive Director

25,000

25.07p

3,204,724

3,229,724

0.77%

Kevin Wilson, Non-Executive Director

50,000

25.07p

617,846

667,846

0.16%

 

 

Enquiries:

 

EKF Diagnostics Holdings plc     

Tel: 029 2071 0570

Julian Baines, CEO 

Mob: 07788 420 859

 

 

Canaccord Genuity Limited

Nominated Adviser/Corporate Broking

Tel: 020 7523 8350

Lucy Tilley /Julian Feneley /Henry Fitzgerald-O'Connor /Chris Connors

 

 

 

 

Walbrook PR Limited 

Tel: 020 7933 8780

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Lianne Cawthorne

Mob: 07584 391 303 or lianne.cawthorne@walbrookpr.com

 

 

About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com

 

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in September 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection.

 

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

 

In March 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2. 

 

In March 2014, EKF acquired Separation Technology, Inc., a Florida based manufacturer of in vitro diagnostics devices for the haematology testing market for a total consideration of $4.0m (c.£2.4m). In April 2014, EKF completed the acquisitions of Selah Genomics Inc., a US based developer of molecular diagnostics for personalised medicine and DiaSpect Medical AB., a Swedish based manufacturer of point-of-care haemoglobin analysers.

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBDGDUIGGBGSI
UK 100

Latest directors dealings